Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Barclays PLC increased its position in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 78.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,281 shares of the company’s stock after buying an additional 55,470 shares during the period. Barclays PLC owned 0.12% of Tango Therapeutics worth $972,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Point72 DIFC Ltd acquired a new stake in Tango Therapeutics in the second quarter valued at approximately $54,000. Quest Partners LLC grew its position in Tango Therapeutics by 1,448.4% in the 3rd quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock valued at $84,000 after purchasing an additional 10,182 shares during the period. Principal Financial Group Inc. bought a new stake in Tango Therapeutics during the 2nd quarter valued at $90,000. Quarry LP acquired a new position in Tango Therapeutics during the second quarter worth $99,000. Finally, SG Americas Securities LLC acquired a new position in shares of Tango Therapeutics during the third quarter valued at about $151,000. 78.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TNGX has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. Guggenheim lowered their target price on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Finally, B. Riley decreased their price target on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics presently has an average rating of “Buy” and an average target price of $13.14.

Insider Activity at Tango Therapeutics

In other news, Director Mace Rothenberg bought 10,000 shares of the business’s stock in a transaction on Monday, November 18th. The stock was acquired at an average price of $3.78 per share, with a total value of $37,800.00. Following the completion of the purchase, the director now directly owns 31,250 shares in the company, valued at $118,125. This represents a 47.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Boxer Capital Management, Llc sold 625,000 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $7.05, for a total transaction of $4,406,250.00. Following the completion of the sale, the insider now owns 7,573,642 shares of the company’s stock, valued at approximately $53,394,176.10. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,338,000 shares of company stock valued at $18,426,160 over the last three months. 6.30% of the stock is owned by corporate insiders.

Tango Therapeutics Stock Down 8.4 %

Shares of NASDAQ TNGX opened at $2.62 on Wednesday. The firm has a market capitalization of $281.44 million, a P/E ratio of -2.22 and a beta of 0.81. The stock’s 50-day simple moving average is $3.33 and its two-hundred day simple moving average is $6.80. Tango Therapeutics, Inc. has a twelve month low of $2.59 and a twelve month high of $13.01.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.